

Fabrication of Polylactic Acid/Paclitaxel Nano Fibers by Electrospinning for Cancer Therapeutics

C. H. Yu

Taoyuan Armed Forces General Hospital

Vincent Chan (✉ vincent.chan@ku.ac.ae)

Khalifa University of Science and Technology <https://orcid.org/0000-0003-2149-4479>

Chuan Li

National Yang-Ming University

J. H. Hsieh

Ming Chi University of Technology

P. H. Lin

National Yang-Ming University

Ya-Hui Tsai

Far East Memorial Hospital

Yun Chen

Far East Memorial Hospital

Research article

Keywords: Polylactic acid, Paclitaxel, Electrospinning, Spin coating, human colorectal carcinoma

Posted Date: September 14th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-52756/v3>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on October 23rd, 2020. See the published version at <https://doi.org/10.1186/s13065-020-00711-4>.

Abstract

Poly(lactic acid) (PLA) is a thermoplastic and biodegradable polyester, largely derived from renewable resources such as corn starch, cassava starch and sugarcane. However, PLA is only soluble in a narrow range of solvents such as tetrahydrofuran, dioxane, chlorinated solvents and heated benzene. The limited choices of solvent for PLA dissolution have imposed significant challenges in the development of specifically engineered PLA nanofibers with electrospinning techniques. Generally, the electrospun polymeric materials have been rendered with unique properties such as high porosity and complex geometry while maintaining its biodegradability and biocompatibility for emerging biomedical applications. In this study, a new anticancer drug delivery system composed of PLA nanofibers with encapsulated paclitaxel was developed by the electrospinning of the respective nanofibers on top of a spin-coated thin film with the same chemical compositions. Our unique approach is meant for promoting strong bonding between PLA-based nanofibers and their respective films in order to improve the prolonged release properties and composite film stability within a fluctuating physicochemical environment during cell culture. PLA/paclitaxel nanofiber supported on respective polymeric films were probed by scanning electron microscope, Fourier transform infrared spectrometer and water contact measurement for determining their surface morphologies, fibers' diameters, molecular vibrational modes, and wettability, respectively. Moreover, PLA/paclitaxel nanofibers supported on respective spin-coated films at different loadings of paclitaxel were evaluated for their abilities in killing human colorectal carcinoma cells (HCT-116). More importantly, MTT assays showed that regardless of the concentrations of paclitaxel, the growth of HCT-116 was effectively inhibited by the prolonged release of paclitaxel from PLA/paclitaxel nanofibers. An effective prolonged delivery system of paclitaxel based on PLA nanofiber-based film has demonstrated exciting potentials for emerging applications as implantable drug delivery patch in post-surgical cancer eradication.

Introduction

Poly(lactic acid) (PLA) is a condensation thermoplastic elastomers with demonstrated low cytotoxicity and good biodegradability and has similar properties compared to those of polypropylene, polyethylene, or polystyrene. Moreover, PLA is an aliphatic (non-aromatic) polymer with a glass transition temperature of around 60°C and melting points between 130 and 180°C. Interestingly, the usage of PLA is highly sustainable because its monomers can be obtained from various types of agricultural by-products such as sugarcane, corn starch or cassava roots and can be later on reused as carbon sources for plants after degradation and decomposition. As a result, PLA is relatively cost-effective for large scale production through direct condensation of lactic acid monomers (~100°C - 160°C) or ring-opening polymerization of lactide on metal catalysts. Most importantly, raw material of PLA can be fabricated into different sizes and shape by various common fabrication techniques such as plastic extrusion, casting, injection molding and spin coating or even 3D printing [1-6]. Thus PLA is an attractive platform for various emerging applications in drug delivery, gene therapy and regenerative medicine.

Paclitaxel (PLX) is an organic compound extracted from the bark of a Pacific yew tree known as *Taxus brevifolia*. It belongs to the taxane family which serves as antineoplastic drugs by inhibiting the disassembly of microtubules in cancerous cells through the binding to intracellular GDP-bound tubulins. The binding as mentioned above directly destabilizes the microtubules by stopping the de-polymerization of β -tubulin dimers from microtubules, leading to the disruptions of cell division during mitotic and interphase cellular functions [7-10]. PLX is a prescribed-only, chemotherapeutic medication to treat a few types of cancer. In clinical setting, PLX currently plays a central role as a chemotherapy medication in the treatment of cervical cancer, breast cancer, ovarian cancer, lung cancer, pancreatic cancer, and Kaposi sarcoma. In general, PLX in its original form or newer albumin-bound formulation is usually administrated to patients by intravenous (IV) injection or infusion. The high efficiency of PLX in anticancer therapy has been proven by the absence of elevated liver enzymes without leading to acute liver injury [11-13]. On the other hand, the current formulation of PLX includes Kolliphor which often causes allergic reactions to patients.

On top of the ideal properties for PLA for biomedical applications random, PLA nanofiber offers complex 3-dimensional microscopic and nanoscale structures for the encapsulation of drugs and hosting of regenerative cells [6]. Moreover, the recent success in using albumin to bound PLX into sub-micron particle, emerging drug delivery system like PLA nanofiber should offer an promising alternative for the prolonged delivery of PLX. In order to evaluate the performance of PLA nanofiber for prolonged PLX delivery, PLA/PLX nanofibers in the form of membrane were fabricated from PLA/PLX mixed solution by electrospinning on top of PLA/PLX thin film with the same composition by spin coating. PLA/PLX thin film spun coated on glass should not lead to significant interference with drug delivery studies involving the supported PLA/PLX nanofibers lying above. Since both thin film and nanofibers as mentioned above had the same chemical composition, strong bonding between the two forms of PLA/PLX should be naturally enforced upon the nanofiber deposition on thin film. To the best of our knowledge, the fabrication of drug delivery patch of PLA/PLX nanofibers immobilized on the same polymer thin film against the change of PLX concentrations aiming for anti-cancer drug delivery has not been reported previously. In this study, the structure, morphology, and compositions of the PLA/PLX nanofibers were thoroughly characterized. In detail, scanning electron microscope (SEM) and Fourier transform infrared spectrometer (FTIR) was applied to probe the nanofiber topology and vibrational modes of chemical bonds, respectively. For exploring the potential of PLA/PLX nanofiber membrane in substained drug delivery for post-surgical site of tumor removal, the tumor killing efficiency of PLA/PLX nanofiber membrane were measured with *in vitro* MTT assays (for cell proliferation and cell cycle) through their biotoxicity against model cell line of neuroblastoma, which is the most common cancer among young children.

Methods

Due to technical limitations, the Methods section can only be accessed as a download in the supplementary files section.

Results

3.1 Morphology of Electrospun PLA

SEM images of plain PLA nanofiber and other PLA nanofiber membranes with different concentrations of encapsulated paclitaxel were presented in Fig. 2. The result indicated that nanofibers of pure PLA and PLA incorporated with paclitaxel displayed uniform fiber size and contour length across the entire region of deposition area while the formation of spindles was negligible after the electrospinning process. Moreover, it was shown that plain PLA nanofibers possessed smooth surface morphology without the formation of detectable pores. To quantify the nanofibers' dimension, the diameter of at least 15 nanofibers were randomly selected from each SEM image of membrane and were measured with image analysis software. The average diameters of nanofibers for three different membrane samples were summarized in Fig. 3. The result indicated that all samples displayed nanofibers with averaged diameters ranging from 0.36 – 0.43 μm .

3.2 Fourier-transform infrared spectroscopy (FTIR)

FTIR reveals the molecular features on polymeric thin-film through the determination of the unique vibrational modes of various chemical groups. FTIR spectra in the range of 500 – 3500 cm^{-1} for spin-coated PLA thin films mixed with different concentrations of paclitaxel (PLA+PTX50% and PLA+PTX100%) were shown in Fig. 4, with all absorption peaks fitted by Gaussian fitting in each sample's spectrum. The FTIR spectra of plain PLA and pure paclitaxol were shown alongside as controls. In general, major FTIR peaks of plain PLA determined by Gaussian fitting included the following vibrational groups: C-O stretch at $\sim 1087 \text{ cm}^{-1}$, C-O-C at $\sim 1183 \text{ cm}^{-1}$, O=C-O in ester groups at $\sim 1755 \text{ cm}^{-1}$, O=C-O stretch in ester groups at $\sim 1130 \text{ cm}^{-1}$ and CH_3 at $\sim 1458 \text{ cm}^{-1}$. The result as mentioned above corresponded well with all the basic chemical groups found along the backbone of PLA. For PTX, major vibrational modes included C-H out-of-plane or C=C=O deformation at 689 cm^{-1} , C-H in-plane deformation at $803\sim 941 \text{ cm}^{-1}$, C-O stretching at $1049\sim 1090 \text{ cm}^{-1}$, C-N stretching at 1274 cm^{-1} , CH_3 deformation at $1330\sim 1380 \text{ cm}^{-1}$, C=C ring stretching at 1444 cm^{-1} , C-C stretching at $1579\sim 1652 \text{ cm}^{-1}$, N-H bending at 1640 cm^{-1} , C=O stretching at $1720\sim 1727 \text{ cm}^{-1}$, (C=O stretching) of amide group at 1733 cm^{-1} , $\text{CH}_3/\text{C-H}$ stretching at $2541\sim 2973 \text{ cm}^{-1}$, $-\text{CH sp}^3$ stretching at 3066 cm^{-1} , N-H/O-H stretching at 3339 cm^{-1} , agreed with those peaks of pure paclitaxel as reported in the literature [4, 6, 14-29]. Those main and minor vibrational modes of plain PLA and pure paclitaxel were summarized in Table 2.

3.3 Contact Angle Measurement

The averaged contact angles of PLA, PLA+PTX50% and PLA+PTX100% nanofiber membrane, supported on respective spun coated thin film were shown in Fig. 5. Regardless of the composition, the water contact angles of all samples were larger than 90° , implying high hydrophobicity displayed on these nanofibers. However, the incorporation of PTX into PLA matrix made the nanofiber coated substrate less

hydrophobic as show by averaged water contact angles of 119.7° and 124.5° in PLA+PTX50% and PLA+PTX100%, respectively, compared to the higher average of of 139.8° in pure PLA.

3.4 Cell Culture

3.4.1. Biocompatibility of Pure PLA Nanofibers and Films

To ensure that PLA or PLA/PTX nanofiber membrane impose negligible cytotoxicity, each sample was immersed in plain culture medium for 72 hours which was subsequently extracted for culturing HCT-116 cells *in-vitro*. For the ease of direct comparison between the three types of nanofiber membranes, MTT data in terms of optical density ratio () instead of individual MTT data. Fig. 6 showed the optical density ratio of HCT-116 cells determined from MTT assay at 48 hours after culturing in the three types of extracted liquid medium. The result indicated that the optical density ratio of HCT-116 cells incubated with extracted culture medium from glass, PLA thin film and PLA nanofiber membrane stays at around one.

3.4.2 Toxicity of PLA/Paclitaxel Mixed Nanofibers

Next, PLA or PLA/paclitaxel nanofiber membrane is immersed in liquid medium for the culture of HCT-116. Fig. 7 presented the optical density ratio from the MTT assay of HCT-116 cells which were cultured in the presence of PLA or PLA/PTX50% or PLA/PTX100% nanofiber membrane in liquid medium for 6 hours, 18 hours and 24 hours. The control group included HCT-116 cells cultured in liquid medium in the prescence of PLA nanofiber membrane. The optical density ratio of HCT-116 cells at each time point was determined as one for the control as mentioned above because there is an absence of paclitaxel in the liquid medium. After 6 hours of culture, the optical density ratio of HCT-116 cells was reduced by 73% and 81% in PLA/PTX50% or PLA/PTX100% containing medium, respectively, compared with that for cells in control group (with PLA nanofiber membrane). Similarly, the optical density ratio of HCT-116 cells was reduced by 78% and 81% in PLA/PTX50% or PLA/PTX100% containing medium, respectively, compared with that for cells in control group after 18 hours of cell culture. The result indicated that the prolonged release of paclitaxel was maintained by the PLA nanofiber carrier within 18 hours of drug adminstation. After 24 hours of cell culture, the optical density ratio of HCT-116 cells was reduced by 33% and 36% in PLA/PTX50% or PLA/PTX100% containing medium, respectively, compared with that for cells in control group after 24 hours of cell culture.

Fig. 8 showed a phase contrast image under 100X magnification of cultured HCT-116 in the presence of PLA or PLA/PTX50% nanofiber membrane in liquid medium after 24 hours of cell seeding. In the absence of paclitaxel in PLA nanofiber sample, HCT-116 cells populating at high density on the membrane surface displayed more elongated cell shpe corresponding to the normal morphology of this cell line as shown by the formation of membrane extensions. In contrast, most HCT-116 cells rounded up by transforming into a circular shape rather than the usual stretched and randomly stack up morphology (see the selected view) due to the loss of proliferative activities of the cancerous cells. At the same time, the cell density on the petri dish was significant reduced by PLA/PTX50% compared to that of PLA. The

result indicated that paclitaxel acted as an effective toxic molecules presented to HCT-116 cells in the liquid medium before the cells were able to adhere on the nanofiber modified surfaces.

3.5 Cell Cycle

Fig. 9 showed the percentage of different phases within the cell cycle of HCT-116 cells after 24 hours of seeding in the liquid medium pre-incubated with PLA or PLA/PTX50% or PLA/PTX100% nanofiber membrane. In spite of the change in the concentrations of paclitaxel in the nanofiber membrane, HCT-116 in the G₁ phase (~60%) overwhelms all others in other phases of cell cycle. Intuitively, G₁ phase occurs when cells grow normally through the synthesis of various enzymes and nutrients for getting ready for DNA replication in the S phase. The result indicated that most HCT-116 cells stay in G₁ phase 24 hours after seeding without going into S phase through the G₁ checkpoint. Secondly, around 20% of cells was at either S or G₂/M phases cultured with liquid medium which was pre-incubated with either PLA or PLA/PTX50% or PLA/PTX100% nanofiber membrane.

Different concentrations of paclitaxel have different impacts on the apoptosis of cancer cells. Under a low concentration (<200 nM), the cell cycle may not be directly affected as paclitaxel may not be able to alter the overall architecture of the microtubules [10, 31-34]. The cell can still maneuver into prometaphase and arrested at the G₂/M phase then followed by p34, cdc2 activation and Bcl-2 phosphorylation, leading to the eventual apoptosis [10, 33-39]. In our cases, the released paclitaxel concentration is estimated at around 32 – 68 nM (see Appendix) for the optical density ratio of 0.26 and 0.19 respectively. It could be concluded that the anticancer effect is attributed to the lower concentration of paclitaxel, which would have a direct impact on the microtubules of HCT-116, e.g., increased difficulty in passing through the S₁ checkpoint but not the overall mitosis [38-42].

Discussion

The emergence of nanocomposites has led to development of advanced thin-film for drug delivery applications [43]. Moreover, the development of new cancer therapeutics requires complementary molecular carriers with new physiochemical properties [44]. A PLA/PTX nanofiber-based thin film was developed herein for the sustained release of cancer therapeutics. SEM was first applied to probe the structure of PLA based nanofibers. Interestingly, the average diameter of plain PLA nanofibers was larger than that of composite nanofibers including PLA+PTX50% and PLA+PTX100%. The trend as mentioned above is brought about by the lower viscosity and more surface charges of PLA/PTX mixture for electrospinning, leading to overcome the surface tension against the formation of a thinner stretch of plain PLA nanofibers [30]. From the FTIR measurements, PLA+PTX50% and PLA+PTX100% were supposed to display absorption peaks of paclitaxel in addition to those of pure PLA but only the main peaks of PLA were detected. Since the mass percentage of PLA in either PLA+PTX50% or PLA+PTX100% nanofibers is significantly larger than that of paclitaxel, the adsorption peaks of paclitaxel with significantly lower signal to noise ratio did not manage to show up in the complexed nanofiber. Numerical

fitting, on the other hand, provided information about absorption peaks that belongs to paclitaxel (data not shown). This serves as a confirmation for the presence of paclitaxel in PLA nanofibers.

From the results of contact angle measurements, it was shown that the complex morphology of nanofiber surface and the mesh-like structures of deposited layer likely influence the interaction between the water droplet and underlying substrate. For instance, water eventually sinks into the porous matrix of the pure PLA nanofiber mesh through diffusion and adsorption, leading to the alteration in hydrophobicity compared to pure PLA coated film [45]. Also, the slight reduction of PLA nanofiber's contact angle upon PTX incorporation is likely caused by the moderation of the solid-liquid interface induced by the complexation between PTX and PLA, as shown in the formation of a hydrogel through the complexation between PLX and amphipathic peptide in aqueous solution [46]. Thus the measurement of water contact angles is only meaningful at the beginning of the test. Nevertheless, the result still can be used as a reference for the relative hydrophilicity among the three types of substrates used herein. The biocompatibility and targeted toxicity of PLA-based nanofiber system were critical to the therapeutic efficacy of the newly developed biomaterial system. Firstly, the MTT results strongly supported that both PLA thin film and PLA nanofiber membrane did not release any toxic debris through its biodegradation, as shown by the unchanged concentration of formazan, relating to cell activity. Interestingly, PLA thin film without the presence of any PLA nanofiber demonstrated the highest cell proliferative activities among all the substrates used herein. The trend as mentioned above was likely caused by the lower hydrophobicity of pure PLA film, in comparison with PLA nanofiber coated substrate, leading to the optimized adsorption of serum protein for promoting cell adhesion and functions [47].

Then MTT assay was used to assess the viability of HCT-116 cells under the influence of PLA/PLX nanofibers. The result strongly supported that both PLA/PTX100% and PLA/PTX50% nanofibers are effective in eradicating cancerous cells. Also, the efficacy of PLA/PTX100% in the eradication of cancerous cells is slightly higher than that of PLA/PTX50% during short term release of paclitaxel. This result implied that the accelerated growth of cancerous cells has led to the elevated depletion of Paclitaxel loading released from the PLA/PTX nanofiber to culture medium. More specifically, the extended proliferation of HCT-116 led to the offset of antineoplastic effect by paclitaxel. However, paclitaxel released from PLA/PTX nanofiber still retained its ability to eradicate HCT-116 cells even after 24 hours of cell seeding. In general, paclitaxel has been known to target tubulin, stopping cell divisions through the intervention of microtubule disassembly, mitotic spindle formation and chromosome segregation within cancerous cells. Most importantly, the result of phase contrast microscopy validated the successful eradication of HCT-116 cells in the cell culture medium, leading to the reduced cell population adhered on the PLA/PTX nanofiber immobilized surface. Thus the presence paclitaxel of in the culture medium should have an direct impact on the morphology of cells. Similar nanofiber-based system has been developed from alginate for the controlled release of silver ions in antimicrobial applications [48].

The results from cell cycle assay revealed that a significant proportion of the cultured cells are in the stage of DNA replication and mitosis in G₂ and M phases, respectively, leading to the separation of

replicated DNA and division into two cells. Thirdly, the percentage of cells in the G₀ phase is smallest (<2.5%) among all phases of cell cycle. The G₀ phase is a period that cells put themselves into a quiescent state, neither dividing nor preparing to divide. Cells decide to move into this phase usually due to some adversary factors or peculiar biological situations. Summarizing these results, we can infer that HCT-116 cells were effectively restrained from DNA replication and subsequent cell division under the current level of released paclitaxel from PLA/PLX nanofiber membrane. One important question is how the released paclitaxel can threaten the growth of HCT-116 during *in-vitro* culture? To answer this question, we need a quantitative estimation of the concentration of paclitaxel in culture media, which is empirically estimated by measuring the optical density ratio from MTT assay on the culture HCT-116 in media mixed with various pre-selected concentrations of paclitaxel. Using conational regression analysis, a fitting function can be determined numerically with statistical errors. Once the fitting function is determined, we can estimate the optical density ratio at a specific concentration of paclitaxel. Details of this estimation are given in the Appendix.

Conclusion

In this study, we fabricated a specially designed PLA platform for cell culture. The electrospun PLA nanofibers mixed with different concentrations of paclitaxel in the form of membrane were deposited on PLA spin-coated thin films of the same compositions. The surface morphology of each type of PLA/PTX nanofiber membrane were first probed with SEM, revealing that the average diameter of rather homogeneous PLA or PLA/PTX nanofibers were about the same, under a uniform distribution under the current setup of electrospinning. Moreover, FTIR confirmed the encapsulation of paclitaxel in PLA nanofiber with the presence of both molecular vibrational modes of PLA and paclitaxel components. These PLA/PTX nanofiber membrane e are also slightly less hydrophobic, based on the high water contact angle in comparison with that of PLA nanofiber membrane. The effect of the encapsulated paclitaxel on the proliferation and cell cycle of cancerous cells was probed with MTT assay and cell cycle assay for HCT-116 cells in liquid culture media pre-incubated with PLA/paclitaxel nanofiber membrane. The results strongly indicated that paclitaxel has a prolonged impact on the cell proliferation up to 24 hours after the seeding. Since the released concentration of paclitaxel is not high (<100nM), it has a subtle impact on the cell cycle through the enforcement of G1 checkpoint, with majority of cells in G1 phase at 24 hours after the seeding. The results have demonstrated the potential of a new PLA/paclitaxel nanofiber-based system as a substained release patch for post-surgical drug delivery of cancer theraxxpeutics.

Declarations

Acknowledgements

Not applicable.

Authors' contributions

Authors HYC and PHL have performed literature research and experimental work. VC and CL carried experimental design, drafted and revised the manuscript. JHH carried formal analysis, supervision, and project administration and reviewed the manuscript. YHT supervised cell culture experiments and instrumentation operations. YH strategizes the project executions and experimental planning, and reviewed the manuscript. All authors read and approved the final manuscript.

Funding

Research reported in this publication was supported by Far Eastern Memorial Hospital under contract number 108DN05. VC was supported by the Khalifa University of Science and Technology under Award No. [CIRA-2018-02]. The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

The data and materials from this study are available from the corresponding authors on reasonable request.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Abbreviations

Polylactic acid: PLA; Paclitaxel: PTX; Fourier-transform infrared spectroscopy: FTIR; Scanning electron microscope: SEM

References

1. Kricheldorf HR, Kreiser-Saunders I, Jürgens C, Wolter D (1996) Polylactides—synthesis, characterization and medical application. *Macromol Symp* 103:85-102
2. Jacobsen S, Fritz HG, Degée Ph, Dubois Ph, Jérôme R (1999) Polylactide (PLA)—a new way of production. *Polym Eng Sci* 39:1311-1319
3. Mihai M, Huneault MA, Favis BD, Li H (2007) Extrusion Foaming of Semi-Crystalline PLA and PLA/Thermoplastic Starch Blends. *Macromol Biosci* 7:907-920

4. Kramschuster A, Turng LS (2010) An injection molding process for manufacturing highly porous and interconnected biodegradable polymer matrices for use as tissue engineering scaffolds. *J Biomed Mater Res B* 92B:366–376
5. Alabbasi A, Liyanaarachchi S, Bobby Kannan M (2012) Polylactic acid coating on a biodegradable magnesium alloy: An in vitro degradation study by electrochemical impedance spectroscopy. *Thin Solid Films* 520:6841–6844
6. Serra T, Planell JA, Navarro M (2013) High-resolution PLA-based composite scaffolds via 3-D printing technology. *Acta Biomater* 9:5521–5530
7. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. *J Clin Oncol* 30:2055-62
8. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai NB, Bhar P, Hawkins M, O'Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. *J Clin Oncol* 23:7794-803
9. Kingston DGI (1991) The chemistry of taxol. *Pharmacol. Ther.* 52:1-34,.
10. Wang TH, Wang HS, Soong YK (2000) Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. *Cancer-Am Cancer Soc* 88:2619-2628
11. Brito DA, Yang Z, Rieder CL, Conly L (2008) Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied. *J Cell Biol* 182:623-629
12. Saville MW, Lietzau J, Pluda JM, Wilson WH, Humphrey RW, Feigel E, Steinberg SM, Broder S, Yarchoan R, Odom J, Feuerstein I (1995) Treatment of HIV-associated Kaposi sarcoma with paclitaxel. *Lancet* 346:26–28
13. Ganguly A, Yang H, Cabral F (2010) Paclitaxel-dependent cell lines reveal a novel drug activity. *Mol. Cancer Ther* 9:2914–2923
14. Chieng BW, Ibrahim NA, Then YY, Loo YY (2014) Epoxidized vegetable oils plasticized poly(lactic acid) biocomposites: mechanical, thermal and morphology properties. *Molecules* 19:16024–16038
15. Boua-In K, Chaiyut N, Ksapabutr B (2010) Preparation of polylactide by ring-opening polymerisation of lactide. *Optoelectron Adv Mat-Rapid Comm* 4:1404–1407,.
16. Hoidy WH, Ahmad MB, Al-Mulla EAJ, Ibrahim NAB (2010) Preparation and characterization of polylactic acid/polycaprolactone clay nanocomposites. *J Appl Sci* 10:97–106
17. Cui M, Liu L, Guo N, Su R, Ma F (2015) Preparation, cell compatibility and degradability of collagen-modified poly(lactic acid). *Molecules* 20:595–607
18. Wang DK, Varanasi S, Fredericks PM, Hill DJT, Symons AL, Whittaker AK, Rasoul F (2013) FT-IR characterization and hydrolysis of PLA-PEG-PLA based copolyester hydrogels with short PLA segments and a cytocompatibility study. *J Polym Sci A Polym Chem* 51:5163–5176

19. Elzein T, Nasser-Eddine M, Delaite C, Bistac S, Dumas P (2004) FTIR study of polycaprolactone chain organization at interfaces. *J Colloid Interf Sci* 273:381–387
20. Khatiwala VK, Shekhar, S. Aggarwal, U. K. Mandal (2008) Biodazsegradation of poly(ϵ -caprolactone) (PCL) film by *Alcaligenes faecalis*. *J Polym Environaaa* 16:61–67
21. Kemala T, Budiando E, Soegiyono B (2012) Preparation and characterization of microspheres based on blend of poly(lactic acid) and poly(ϵ -caprolactone) with poly(vinyl alcohol) as emulsifier. *Arab J Chem* 5:103-108
22. Benkaddour A, Jradi K, Robert S, Daneault C (2013) Grafting of polycaprolactone on oxidized nanocelluloses by click chemistry. *Nanomaterials* 3:141-157
23. Yu H, Jia Y, Yao C, Lu Y (2014) PCL/PEG core/sheath fibers with controlled drug release rate fabricated on the basis of a novel combined technique. *Int J Pharm* 469:17-22
24. Liu H, Zhang B, Shi H, Jiao K, Fu X (2009) Biomolecule-assisted hydrothermal synthesis ZnSe nanocrystallites and its application as oligonucleotides label. *J Disper Sci Technol* 30:495-499
25. Linder R, Seefeld K, Vavra A, Kleinermanns K (2008) Gas phase infrared spectra of nonaromatic concentrations of paclitaxel. *Chem Phys Lett* 453:1-6
26. Hansrot MZ, "Detection of some aliphatic concentrations of paclitaxel using MALDI-TOF MS and FTIR," M. S. thesis, biochemistry with professional experience BSc (Hons), University of Leeds, UK, Aug. 2013. Accessed on: Sep. 19, 2018. [Online]. Available: <https://www.researchgate.net/publication/258516824>.
27. Venkatasubbu GD, Ramasamy S, Avadhani G., Ramakrishnan V, Kumar J (2013) Surface modification and paclitaxel drug delivery of folic acid modified polyethylene glycol functionalized hydroxyapatite nanoparticles. *Powder Technol* 235:437-442
28. Totiger SB, Hiremath JG (2011) Paclitaxel loaded poly (sebacic acid-co-ricinoleic ester anhydride)-based nanoparticles. *Asian J Pharm* 5:225-230
29. Devi TSR, Gayathri S (2010) FTIR and FT-Raman spectral analysis of paclitaxel drugs. *Int J Pharm Sci Rev Res* 2:106-110
30. Chen Y, Lin J, Fei Y, Wang H, Gao W (2010) Preparation and characterization of electrospinning PLA/curcumin composite membranes. *Fibers Polym* 11:1128-1131
31. Ponnathpur V, Ibrado AM, Reed JC, Ray S, Huang Y, Self S, Bullock G, Nawabi A, Bhalla K, (1995) Effects of modulators of protein kinases on taxol-induced apoptosis of human leukemic cells possessing disparate levels of p26BCL-2 protein. *Clin Cancer Res* 1:1399-1406
32. Wolfson M, Yang CPH, Horwitz SB (1997) Taxol induces tyrosine phosphorylation of Shc and its association with Grb2 in murine RAW 264.7 cells. *Int J Cancer* 70:248-252
33. Sorger PK, Dobles M, Tournebize R, Hyman AA (1997) Coupling cell division and cell death to microtubule dynamics. *Curr Opin Cell Biol* 9:807-814
34. Li Y, Benezra R (1996) Identification of a human mitotic checkpoint gene: hsMAD2. *Science* 274:246-248

35. Li Y, Gorbea C, Mahaffey D, Rechsteiner M, Benezra R (1997) MAD2 associates with the cyclosome/anaphase-promoting complex and inhibits its activity. *Proc Natl Acad Sci USA* 94:12431-12436
36. Taylor SS, McKeon F (1997) Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage. *Cell* 89:727-735
37. Taylor SS, Ha E, McKeon F. (1998) The human homologue of Bub3 is required for kinetochore localization of Bub1 and a Mad3/Bub1-related protein kinase. *J Cell Biol* 142:1-11
38. Minshull J, Straight A, Rudner AD, Dernburg AF, Belmont A, Murray AW (1996) Protein phosphatase 2A regulates MPF activity and sister chromatid cohesion in budding yeast. *Curr Biol* 6:1609-1620
39. Minshull J, Sun H, Tonks NK, Murray AW (1994) A MAP kinase-dependent spindle assembly checkpoint in *Xenopus* egg extracts. *Cell* 79:475-486
40. Wang TH, Wang HS, Soong YK (2000) Paclitaxel-induced cell death where the cell cycle and apoptosis come together. *Cancer*, 88:2619-2628
41. Ren X, Zhao B, Chang H, Xiao M, Wu Y, Liu Y (2018) Paclitaxel suppresses proliferation and induces apoptosis through regulation of ROS and the AKT/MAPK signaling pathway in canine mammary gland tumor cells. *Mol Med* 17:8289-8299
42. Huisman C, Ferreira CG., Bröker LE, Rodriguez J. A, Smit EF, Postmus PE, Kruyt FAE, Giaccone G (2002) Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H4601. *Clin. Cancer Res* 8:596-606
43. Ates B, Koytepe S, Ulu A, Canbolat Gurses, Thakur VK (2020) Chemistry, structures, and advanced applications of nanocomposites from biorenewable resources. *Chem Rev* (<https://doi.org/10.1021/acs.chemrev.9b00553>)
44. Sharma PC, Goyal R, Sharma A, Sharma D, Saini N, Rajak H, Sharma S, Thakur VK (2020) Insights on fluoroquinolones in cancer therapy: chemistry and recent developments. *Mat Today Chem* 17: 100296
45. Lertphirun K, Srikulkit K (2019) Properties of poly(lactic acid) filled with hydrophobic cellulose/SiO₂ composites. *Int J Poly Sci* 2019: 7835172
46. Liu J, Zhang L, Yang X, Zhao X (2011) Controlled release of paclitaxel from a self-assembling peptide hydrogel formed in situ and antitumor study in vitro. *Int J Nanomedicine* 6: 2143–2153
47. Qi Y, Ma HL, Du ZH, Yang B, Wu J, Wang R, Zhang XQ (2019) Hydrophilic and antibacterial modification of poly(lactic acid) films by γ -ray irradiation," *ACS Omega* 4:21439–21445
48. Wróblewska-Krepsztul J, Rydzkowski T, Michalska-Požoga I, Thakur VK (2019) Biopolymers for biomedical and pharmaceutical applications: recent advances and overview of alginate electrospinning. *Nanomaterials* 9:404

Tables

Process Parameters for PLA/Paclitaxel Films by Spin Coating	
Speed (rpm)	3000
Operational temperature (°C)	Room temperature
Deposition time (min)	4
PLA concentration in TFA (wt. %)	40
Paclitaxel concentration in DMSO	2.5 mg/100 ml (50%), 5 mg/100 ml (100%)

Process Parameters for PLA/Paclitaxel Nanofibers by Electrospinning	
Voltage (kV)	17
Flow Rate (ml/min)	1×10^{-2}
Syringe Outer/Inner Diameter (mm)	$5.0 \times 10^{-1}/2.6 \times 10^{-1}$
Operational temperature (°C)	Room temperature
Working Distance (cm)	14 or 15
Deposition time (sec)	>60
PLA concentration in TFA (wt. %)	40
Paclitaxel concentration in DMSO	2.5 mg/1 ml (50%), 5 mg/1 ml (100%)
Volumetric mixing ratio (PLA: Paclitaxel)	3 ml: 200 ml

Table 1 Parameters for deposition of PLA/paclitaxel mixed layer film by spin coating and nanofibers by electrospinning.

PLA

Wavenumber (cm ⁻¹)	Mode
616	COO- bend
806	COO- (out-of-plane)
973	C-N stretching
1022	-CH ₂ (out-of-plane)
1090	C-O stretching
1183	-C-O-C-
1224	-C-O-H-
1305	C-H (out-of-plane)
1339	C-H bending
1434	COO- symmetric stretching
1470	-CH ₂ bending
1601	COO- asymmetric stretching
1746	C=O stretching
2905	C-H stretching
2956	-CH ₂ symmetric stretching
3004	-CH ₂ asymmetric stretching
3568	OH (COOH)
3572	OH (COOH)

Paclitaxel

Wavenumber (cm ⁻¹)	Mode
689	C-H out-of-plane/C-C=O deformation
803-941	C-H in-plane deformation
941-803	C-H in-plane deformation
1049-1090	C-O stretching
1112-1117	O-H in-plane bending in (COOH)
1274	C-N stretching
1330-1380	CH ₃ deformation
1369	CH/NH bend
1444	C=C ring stretching
1579-1652	C-C stretching
1640	N-H bending
1733	(C=O stretching) of amide group
1775	C=O
1777	C=O
2541-2973	CH ₃ /C-H stretching
2860	CH
2909	CH stretch
3066	-CH sp ³ stretching
3339	N-H/O-H stretching
3568	OH (COOH)
3572	OH (COOH)

Table 2 Selected FTIR absorption peaks for PLA [14-24] and paclitaxel [14-29].

Figures




Figure 1

Experiment study for the electrospun paclitaxel mixed PLA nanofibers on top of a thin film of same compositions.






Figure 2

Morphology of electrospun PLA/paclitaxel mixed nanofibers.




Figure 3

Averaged diameters for electrospun PLA/paclitaxel mixed nanofibers. At least 30 fibers are randomly selected from each image of SEM.




Figure 4

FTIR spectra for electrospun PLA layer films with different concentrations of paclitaxel.




Figure 5

Contact angle for PLA/paclitaxel mixed nanofibers. All photos are images of water drops on nanofibers.




Figure 6

Contact angle for PLA/paclitaxel mixed nanofibers. All photos are images of water drops on nanofibers.




Figure 7

MTT assay for HCT-116 cultured in media with PLA nanofibers mixed with different concentrations of paclitaxel. The optical density is $[\log]_{10} ((\text{incident light intensity}) / (\text{transmitted light intensity}))$ and the optical density ratio is $(OD_{(\text{specific group})}) / OD_{\text{control}}$.





Figure 8

The 100X optical images of cultured HCT-116 on PLA or PLA/PTX50% nanofiber membrane.




Figure 9

Percentage of different phases in the cell cycle (24 hours after seeding) of HCT-116 cultured in media drawn from immersed PLA/paclitaxel mixed nanofibers.




Figure 10

The benchmark test for the optical density ratio from MTT assay on the culture of HCT-116 as a function of paclitaxel concentration in the culture medium.